Jeffrey Meyehardt, MD of Harvard Medical School discusses the optimal duration of therapy for patients with stage III colon cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
Jeffrey Meyehardt, MD of Harvard Medical School discusses the optimal duration of therapy for patients with stage III colon cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.